02 April 2022: Clinical Research
Impact of Primary Tumor Resection on Survival of Patients with Metastatic Gallbladder Carcinoma: A Population-Based, Propensity Matched Study
Jiang Xie E* , Zuofu Liao C* , Chao Sun A , Zhonghao Chen AF*DOI: 10.12659/MSM.934447
Med Sci Monit 2022; 28:e934447
Table 3 The distribution of clinicopathological variables with standardized difference before and after propensity score matching.
| Variables | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| Non-surgeryN=841 | SurgeryN=496 | SD | Non-surgeryN=185 | SurgeryN=185 | SD | |
| 0.212 | 0.035 | |||||
| Female | 561 (66.7%) | 378 (76.2%) | 131 (70.8%) | 128 (69.2%) | ||
| Male | 280 (33.3%) | 118 (23.8%) | 54 (29.2%) | 57 (30.8%) | ||
| 0.175 | 0.130 | |||||
| Black | 136 (16.2%) | 61 (12.3%) | 20 (10.8%) | 28 (15.1%) | ||
| White | 598 (71.1%) | 390 (78.6%) | 145 (78.4%) | 139 (75.1%) | ||
| Other | 107 (12.74%) | 45 (9.07%) | 20 (10.8%) | 18 (9.73%) | ||
| 0.062 | 0.119 | |||||
| ≤65 | 371 (44.1%) | 234 (47.2%) | 83 (44.9%) | 94 (50.8%) | ||
| >65 | 470 (55.9%) | 262 (52.8%) | 102 (55.1%) | 91 (49.2%) | ||
| 0.119 | 0.023 | |||||
| Married | 441 (52.4%) | 289 (58.3%) | 105 (56.8%) | 103 (55.7%) | ||
| Unmarried | 360 (42.8%) | 188 (37.9%) | 68 (36.8%) | 70 (37.8%) | ||
| Unknown | 40 (4.76%) | 19 (3.83%) | 12 (6.49%) | 12 (6.49%) | ||
| 1.889 | 0.124 | |||||
| I | 7 (0.83%) | 38 (7.66%) | 6 (3.24%) | 6 (3.24%) | ||
| II | 58 (6.90%) | 180 (36.3%) | 44 (23.8%) | 44 (23.8%) | ||
| III | 128 (15.2%) | 213 (42.9%) | 82 (44.3%) | 83 (44.9%) | ||
| IV | 7 (0.83%) | 21 (4.23%) | 5 (2.70%) | 9 (4.86%) | ||
| Unknown | 641 (76.2%) | 44 (8.87%) | 48 (25.9%) | 43 (23.2%) | ||
| 1.39 | 0.120 | |||||
| T1 | 113 (13.4%) | 25 (5.04%) | 24 (13.0%) | 22 (11.9%) | ||
| T2 | 6 (0.71%) | 151 (30.4%) | 5 (2.70%) | 6 (3.24%) | ||
| T3 | 345 (41.0%) | 285 (57.5%) | 133 (71.9%) | 130 (70.3%) | ||
| T4 | 69 (8.20%) | 21 (4.23%) | 9 (4.86%) | 14 (7.57%) | ||
| Unknown | 308 (36.6%) | 14 (2.82%) | 14 (7.57%) | 13 (7.03%) | ||
| 0.408 | 0.028 | |||||
| N0 | 348 (41.4%) | 266 (53.6%) | 86 (46.5%) | 84 (45.4%) | ||
| N1 | 219 (26.0%) | 151 (30.4%) | 55 (29.7%) | 55 (29.7%) | ||
| N2 | 126 (15.0%) | 44 (8.87%) | 27 (14.6%) | 28 (15.1%) | ||
| Unknown | 148 (17.6%) | 35 (7.06%) | 17 (9.19%) | 18 (9.73%) | ||
| 0.139 | 0.020 | |||||
| None/Unknown | 784 (93.2%) | 443 (89.3%) | 169 (91.4%) | 170 (91.9%) | ||
| Yes | 57 (6.78%) | 53 (10.7%) | 16 (8.65%) | 15 (8.11%) | ||
| 0.122 | 0.034 | |||||
| No/Unknown | 326 (38.8%) | 222 (44.8%) | 65 (35.1%) | 68 (36.8%) | ||
| Yes | 515 (61.2%) | 274 (55.2%) | 120 (64.9%) | 117 (63.2%) | ||
| 0.605 | 0.118 | |||||
| ≤1 | 23 (2.73%) | 14 (2.82%) | 5 (2.70%) | 6 (3.24%) | ||
| ≤3 | 64 (7.61%) | 121 (24.4%) | 21 (11.4%) | 22 (11.9%) | ||
| ≤5 | 91 (10.8%) | 92 (18.5%) | 28 (15.1%) | 29 (15.7%) | ||
| >5 | 153 (18.2%) | 87 (17.5%) | 39 (21.1%) | 46 (24.9%) | ||
| Unknown | 510 (60.6%) | 182 (36.7%) | 92 (49.7%) | 82 (44.3%) | ||
| 0.305 | 0.140 | |||||
| Adenocarcinomas | 655 (77.9%) | 416 (83.9%) | 153 (82.7%) | 145 (78.4%) | ||
| Epithelial | 103 (12.2%) | 32 (6.45%) | 16 (8.65%) | 20 (10.8%) | ||
| Mucinous | 29 (3.45%) | 34 (6.85%) | 11 (5.95%) | 11 (5.95%) | ||
| Others | 54 (6.42%) | 14 (2.82%) | 5 (2.70%) | 9 (4.86%) | ||